Jon E. Charlesworth
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jon E. Charlesworth.
Diabetes | 1996
Marta E. Couce; Laurie A. Kane; Timothy D. O'Brien; Jon E. Charlesworth; Walter C. Soeller; John D. McNeish; David K. Kreutter; Patrick C. Roche; Peter C. Butler
Islet amyloid derived from islet amyloid polypeptide (IAPP) is a well-recognized feature of type II diabetes. However, the mechanism of islet amyloidogenesis is unknown. In vitro studies suggest that amino acid residues 20–29 in human, but not mouse, IAPP confer amyloidogenicity consistent with the absence of spontaneous islet amyloidosis in mice. Several clinical and in vitro studies suggest that increased synthetic rates of IAPP predispose to IAPP-amyloidosis. In the present study, we sought to test the hypothesis that pharmacological induction of insulin resistance in a mouse transgenic (TG) for human IAPP would induce islet amyloid and β-cell dysfunction. TG and non-transgenic (N-TG) control mice were treated with both rat growth hormone (12 μg/day) and dexamethasone (0.24 mg/day) (dex/GH) or received no treatment for 4 weeks, after which animals were killed to examine islet morphology. Treatment with dex/GH caused hyperglycemia (7.3 ± 0.4 vs. 5.2 ± 0.1 mmol/l, TG vs. N-TG, P < 0.001) associated with a decreased plasma insulin concentration (595 ± 51 vs. 996 ± 100 pmol/1, TG vs. N-TG, P < 0.05) in TG versus control mice. Islet amyloid was induced in treated TG mice but not in control mice. Islet amyloid was identified in both intra- and extracellular deposits, the former being associated with evidence of β-cell degeneration. We conclude that dex/GH treatment in mice TG for human IAPP induces IAPP-derived islet amyloid, hyperglycemia, and islet dysfunction. The present model recapitulates the islet morphology and phenotype of type II diabetes.
Acta Biomaterialia | 2012
Mahrokh Dadsetan; Melissa Giuliani; Florian Wanivenhaus; M. Brett Runge; Jon E. Charlesworth; Michael J. Yaszemski
In this work, we have investigated the development of a synthetic hydrogel that contains a negatively charged phosphate group for use as a substrate for bone cell attachment and differentiation in culture. The photoreactive, phosphate-containing molecule, bis(2-(methacryloyloxy)ethyl)phosphate (BP), was incorporated into oligo(polyethylene glycol) fumarate hydrogel and the mechanical, rheological and thermal properties of the resulting hydrogels were characterized. Our results showed changes in hydrogel compression and storage moduli with incorporation of BP. The modification also resulted in decreased crystallinity as recorded by differential scanning calorimetry. Our data revealed that incorporation of BP improved attachment and differentiation of human fetal osteoblast (hFOB) cells in a dose-dependent manner. A change in surface chemistry and mineralization of the phosphate-containing surfaces verified by scanning electron microscopy and energy dispersive X-ray analysis was found to be important for hFOB cell attachment and differentiation. We also demonstrated that phosphate-containing hydrogels support attachment and differentiation of primary bone marrow stromal cells. These findings suggest that BP-modified hydrogels are capable of sustaining attachment and differentiation of both bone marrow stromal cells and osteoblasts that are critical for bone regeneration.
Acta Biomaterialia | 2010
Farooq A. Shiekh; Jon E. Charlesworth; Sung Hoon Kim; Larry W. Hunter; Muthuvel Jayachandran; Virginia M. Miller; John C. Lieske
Calcifying biological nanoparticles (NPs) develop under cell culture conditions from homogenates of diverse tissue samples displaying extraosseous mineralization, including kidney stones and calcified aneurysms. Probes to definitively identify NPs in biological systems are lacking. Therefore, the aim of this study was to begin to establish a proteomic biosignature of NPs in order to facilitate more definitive investigation of their contribution to disease. Biological NPs derived from human kidney stones and calcified aneurysms were completely decalcified by overnight treatment with ethylenediaminetetraacetic acid or brief incubation in HCl, as evidenced by lack of a calcium shell and of Alizarin Red S staining, by transmission electron microscopy and confocal microscopy, respectively. Decalcified NPs contained numerous proteins, including some from bovine serum and others of prokaryotic origin. Most prominent of the latter group was EF-Tu, which appeared to be identical to EF-Tu from Staphylococcus epidermidis. A monoclonal antibody against human EF-Tu recognized a protein in Western blots of total NP lysate, as well as in intact NPs by immunofluorescence and immunogold EM. Approximately 8% of NPs were quantitatively recognized by the antibody using flow cytometry. Therefore, we have defined methods to reproducibly decalcify biological NPs, and identified key components of their proteome. These elements, including EF-Tu, can be used as biomarkers to further define the processes that mediate propagation of biological NPs and their contribution to disease.
Journal of the American College of Cardiology | 2002
Todd E. Rasmussen; Brenda L. Kirkland; Jon E. Charlesworth; George P. Rodgers; Sandra R. Severson; Jeri C. Rodgers; Robert L. Folk; Virginia M. Miller
Background: Definitive mechanisms causing vascular calcification are unknown. Experiments were designed to evaluate explanted calcified human vascular tissue for the presence of nanometer-scale objects hypothesized to be a type of bacteria associated with calcified geological specimens and human kidney stones (Folk RL; J Sed Petrology 63:990-999, 1993; Kajander EO, et al., PNAS 95:8274-9279, 1998).
International Journal of Nanomedicine | 2014
Larry W. Hunter; Jon E. Charlesworth; Sam Yu; John C. Lieske; Virginia M. Miller
Background Nano-sized complexes of calcium phosphate mineral and proteins (calcifying nanoparticles [CNPs]) serve as mineral chaperones. Thus, CNPs may be both a result and cause of soft tissue calcification processes. This study determined if CNPs could augment calcification of arterial vascular smooth muscle cells in vitro. Methods CNPs 210 nm in diameter were propagated in vitro from human serum. Porcine aortic smooth muscle cells were cultured for up to 28 days in medium in the absence (control) or presence of 2 mM phosphate ([P] positive calcification control) or after a single 3-day exposure to CNPs. Transmission electron-microscopy was used to characterize CNPs and to examine their cellular uptake. Calcium deposits were visualized by light microscopy and von Kossa staining and were quantified by colorimetry. Cell viability was quantified by confocal microscopy of live-/dead-stained cells and apoptosis was examined concurrently by fluorescent labeling of exposed phosphatidylserine. Results CNPs, as well as smaller calcium crystals, were observed by transmission electron-microscopy on day 3 in CNP-treated but not P-treated cells. By day 28, calcium deposits were visible in similar amounts within multicellular nodules of both CNP- and P-treated cells. Apoptosis increased with cell density under all treatments. CNP treatment augmented the density of apoptotic bodies and cellular debris in association with mineralized multicellular nodules. Conclusion Exogenous CNPs are taken up by aortic smooth muscle cells in vitro and potentiate accumulation of smooth-muscle-derived apoptotic bodies at sites of mineralization. Thus, CNPs may accelerate vascular calcification.
Mayo Clinic Proceedings | 2003
Vilmarie Rodriguez; William L. Nichols; Jon E. Charlesworth; James G. White
Sebastian platelet syndrome is a rare autosomal dominant disorder characterized by macrothrombocytopenia with granulocyte inclusions similar to those in patients with Fechtner platelet syndrome but without evidence of hereditary nephritis and sensorineural hearing loss that characterizes the latter. Although by light microscopy the granulocyte inclusions in these disorders appear morphologically similar to those found in May-Hegglin anomaly, another autosomal dominant macrothrombocytopenia, by electron microscopy the inclusions are distinct. Studies of platelet function usually suggest normal or near-normal platelet function, although mild bleeding symptoms can be associated with each of these disorders. We describe a 38-year-old woman and her 11-year-old daughter who presented with lifelong histories of mild thrombocytopenia and easy bruising. Detailed hemostatic studies showed prolonged bleeding times in the child and the mother, with the child having absent secondary wave platelet aggregation responses to epinephrine, also reflected by testing with the platelet function analyzer (PFA-100 device). The mothers hemostatic studies were normal including platelet aggregometry, PFA-100 testing, and platelet flow cytometry. By light microscopy the blood smears of both individuals showed neutrophil inclusions, and their platelets were mildly enlarged but were not giant. Electron microscopy showed the neutrophil inclusions seen in classic Sebastian platelet syndrome or Fechtner platelet syndrome. These 2 cases expand the description of Sebastian platelet syndrome to include individuals with large but not giant platelets and mild or minimal thrombocytopenia. The differential diagnosis of hereditary thrombocytopenias is reviewed briefly.
Platelets | 2018
Dong Chen; Cindy B. Uhl; Sandra C. Bryant; Marcy Krumwiede; Ryan L. Barness; Mary C. Olson; Susan C. Gossman; Sibel Erdogan Damgard; Scott I. Gamb; Lisa A. Cummins; Jon E. Charlesworth; Christina M. Wood-Wentz; Jeffrey L. Salisbury; Elizabeth A. Plumhoff; Elizabeth M. Van Cott; Rong He; Deepti M. Warad; Rajiv K. Pruthi; John A. Heit; William L. Nichols; James G. White
Abstract Platelet transmission electron microscopy (PTEM) is considered the gold standard test for assessing distinct ultrastructural abnormalities in inherited platelet disorders (IPDs). Nevertheless, PTEM remains mainly a research tool due to the lack of standardized procedures, a validated dense granule (DG) count reference range, and standardized image interpretation criteria. The aim of this study was to standardize and validate PTEM as a clinical laboratory test. Based on previously established methods, we optimized and standardized preanalytical, analytical, and postanalytical procedures for both whole mount (WM) and thin section (TS) PTEM. Mean number of DG/platelet (plt), percentage of plts without DG, platelet count (PC), mean platelet volume (MPV), immature platelet fraction (IPF), and plt light transmission aggregometry analyses were measured on blood samples from 113 healthy donors. Quantile regression was used to estimate the reference range for DG/plt, and linear regression was used to assess the association of DG/plt with other plt measurements. All PTEM procedures were standardized using commercially available materials and reagents. DG interpretation criteria were established based on previous publications and expert consensus, and resulted in improved operator agreement. Mean DG/plt was stable for 2 days after blood sample collection. The median within patient coefficient of variation for mean DG/plt was 22.2%; the mean DG/plt reference range (mid-95th %) was 1.2–4.0. Mean DG/plt was associated with IPF (p = .01, R2 = 0.06) but not age, sex, PC, MPV, or plt maximum aggregation or primary slope of aggregation (p > .17, R2 < 0.02). Baseline ultrastructural features were established for TS-PTEM. PTEM was validated using samples from patients with previously established diagnoses of IPDs. Standardization and validation of PTEM procedures and interpretation, and establishment of the normal mean DG/plt reference range and PTEM baseline ultrastructural features, will facilitate implementation of PTEM as a valid clinical laboratory test for evaluating ultrastructural abnormalities in IPDs.
American Journal of Clinical Pathology | 2017
Juliana Perez Botero; Deepti M. Warad; Rong He; Cindy B. Uhl; Shulan Tian; Gregory E. Otteson; Ryan L. Barness; Mary C. Olson; Susan C. Gossman; Jon E. Charlesworth; William L. Nichols; Rajiv K. Pruthi; Dong Chen
Objectives Patients with hereditary/congenital platelet disorders (HPDs) have a broad range of clinical manifestations and laboratory phenotypes. We assessed the performance characteristics of the International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT) and clinically validated platelet laboratory tests for diagnosis of HPDs. Methods The records of 61 patients with suspected HPDs were reviewed and ISTH-BAT scores calculated. Results Nineteen (31%) patients had thrombocytopenia, and 46 (75%) had positive ISTH-BAT scores. Thirteen and 17 patients had prolonged PFA-100 (Dade Behring, Miami, FL) adenosine diphosphate and epinephrine closure times, respectively. Twenty-two had abnormal platelet light transmission aggregation. Twenty-four had platelet transmission electron microscopy (PTEM) abnormalities (10 dense granule deficiency, 14 other ultrastructural abnormalities). Positive ISTH-BAT scores were associated with thrombocytopenia (P < .0001) and abnormal PTEM (P = .002). Twenty-three patients had normal results. Conclusions ISTH-BAT identified patients with suspected HPDs but lacked a robust association with laboratory abnormalities. Despite comprehensive laboratory testing, some patients may have normal results.
Journal of the American College of Cardiology | 2004
John C. Lieske; Vivek Kumar; Gerard Farell-Baril; Shihui Yu; Jon E. Charlesworth; Ewa Rzewuska-Lech; Peter LaBreche; Sandra R. Severson; Virginia M. Miller
Detection and Propagation of Calcified Nanostructures From Human Aneurysms John C. Lieske, Vivek Kumar, Gerard Farell-Baril, Shihui Yu, Jon E. Charlesworth, Ewa Rzewuska-Lech, Peter LaBreche, Sandra R. Severson, Virginia M. Miller, Mayo Clinic Rochester, Rochester, MN Background: Mechanisms leading to vascular calcification remain incompletely understood. Nanometer-sized, mineralized structures recognized by a commercially available monoclonal antibody (8D10, Nanobac OY) are present in calcified human aneurysms. These structures were not detected by TUNEL staining, suggesting they were not apoptotic bodies. The 8D10 antibody is directed against nanobacteria, a controversial, slow-growing, and calcifying microorganism. Therefore, experiments were designed to determine whether structures from aneurysms are viable, nano-sized organisrns. Methods: Aneurysms (n=3) collected as surgical waste were decalcified, sterile filtered (0.22 μm), and cultured in DMEM containing gamma-irradiated calf serum. Results: In 2 of 3 cultures micron-sized particles visible by light microscopy increased in number over 4-6 weeks. The negative culture came from an aneurysm without stainable nanoparticles. With transmission electron microscopy (EM), cultured particles showed an inner core surrounded by a shell of calcium phosphate (documented via energy dispersive microanalysis). After dissolution of the shell with EDTA, spherical structures of 50-100 nm were seen by scanning EM. These cultured particles incorporated [H]uridine at a rate 2.3 times greater than control cultures of DMEM containing serum and inorganic hydroxyapatite (HA) crystals (P<0.01). Therefore, these nanostructures appear to synthesize RNA. Particles cultured from aneurysms also stained with the 8D10 antibody, and SDS-PAGE of extracted proteins revealed multiple distinct bands, including one (Mr 47 kDa) recognized by the 8D10 antibody. The pattern of proteins extracted from inorganic HA crystals incubated with DMEM and calf serum did not contain the 47-kDa band recognized by the 8D10 antibody. Conclusion: In conclusion, these results suggest that viable nano-sized organisms are present within calcified human arterial tissue. A cause and effect relationship between the presence of these organisms and development of arterial calcification remains to be determined. This was presented at the American College of Cardiology Annual Scientific Session 2004 in New Orleans, LA on March 8, 2004
Biophysical Journal | 2006
Thomas P. Burghardt; Jon E. Charlesworth; Miriam F. Halstead; James E. Tarara; Katalin Ajtai